Pharma
Zydus Lifesciences Ltd
ZYDUSLIFE · NSE · INE010B01027Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE20.1%
ROCE18.9%
ROE20.1%
1Y Return+26.87%
Avg. Volume1.4M
Price Chart
About
Zydus Lifesciences Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price—
52W High / Low—
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE20.1%
1Y Return+26.87%
Day Change—
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹28,592 Cr | ₹27,148 Cr | ₹23,242 Cr | ||||||||||
| Expenses | ₹20,276 Cr | ₹18,673 Cr | ₹16,183 Cr | ||||||||||
| Operating Profit | ₹8,316 Cr | ₹8,475 Cr | ₹7,058 Cr | ||||||||||
| OPM % | 29.0% | 31.0% | 30.0% | ||||||||||
| Other Income | ₹-74 Cr | ₹-7 Cr | ₹50 Cr | ||||||||||
| Depreciation | ₹1,725 Cr | ₹1,408 Cr | ₹916 Cr | ||||||||||
| Interest | ₹510 Cr | ₹439 Cr | ₹166 Cr | ||||||||||
| Profit Before Tax | ₹6,007 Cr | ₹6,621 Cr | ₹6,027 Cr | ||||||||||
| Tax | ₹1,414 Cr | ₹1,497 Cr | ₹1,354 Cr | ||||||||||
| Net Profit | ₹4,593 Cr | ₹5,124 Cr | ₹4,673 Cr | ||||||||||
| EPS (₹) | 44.9 | 50.1 | 45.0 | ||||||||||
| Dividend Payout % | — | 2% | 24% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹8,017 Cr | ₹7,587 Cr | ₹6,864 Cr | ₹6,123 Cr | |||||||||
| Expenses | ₹6,088 Cr | ₹5,033 Cr | ₹5,048 Cr | ₹4,107 Cr | |||||||||
| Operating Profit | ₹1,929 Cr | ₹2,554 Cr | ₹1,816 Cr | ₹2,016 Cr | |||||||||
| OPM % | 24.0% | 34.0% | 26.0% | 33.0% | |||||||||
| Depreciation | ₹555 Cr | ₹508 Cr | ₹360 Cr | ₹302 Cr | |||||||||
| Interest | ₹156 Cr | ₹123 Cr | ₹130 Cr | ₹101 Cr | |||||||||
| Net Profit | ₹990 Cr | ₹1,341 Cr | ₹1,023 Cr | ₹1,239 Cr | |||||||||
| EPS (₹) | 9.4 | 12.7 | 10.4 | 12.5 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹101 Cr | ₹101 Cr | ₹101 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹27,011 Cr | ₹23,852 Cr | ₹19,729 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹12,496 Cr | ₹3,213 Cr | ₹804 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹11,065 Cr | ₹9,523 Cr | ₹8,200 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹50,673 Cr | ₹36,689 Cr | ₹28,834 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹24,106 Cr | ₹13,134 Cr | ₹12,368 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹7,540 Cr | ₹6,412 Cr | ₹1,220 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹15,328 Cr | ₹14,451 Cr | ₹12,822 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹50,673 Cr | ₹36,689 Cr | ₹28,834 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹2,117 Cr | ₹-7,895 Cr | ₹5,807 Cr | ₹28 Cr |
| FY25 | ₹6,781 Cr | ₹-8,363 Cr | ₹1,995 Cr | ₹414 Cr |
| FY24 | ₹3,228 Cr | ₹-1,492 Cr | ₹-1,810 Cr | ₹-75 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | — | — | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | — | — | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.2 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,494 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | ₹53,782 Cr | 33.6 | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-10-24Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE Filing2026-08-12Zydus Lifesciences Ltd (BOM:532321) (Q1 2027) Earnings Call Highlights: Robust 66. ...GuruFocus.com2026-08-11Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)PR Newswire2026-08-11Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)GlobeNewswire2026-06-16Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027Business Wire
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.